Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 1, 2000, Pages 139-146

  Moghetti, P ^a   Castello, R ^a   Negri, C ^a   Tosi, F ^a   Perrone, F ^a   Caputo, M ^b   Zanolin, E ^a   Muggeo, M ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; INSULIN; METFORMIN; PLACEBO;

ARTICLE; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FOLLOW UP; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MENSTRUATION; MENSTRUATION DISORDER; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034458234     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.1.139     Document Type: Article

References (34)

1. Polycystic ovary syndrome
2. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis
3. Insulin stimulates androgen accumulation In incubations of ovarian stroma obtained from women with hyperandrogenism
4. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome
5. Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: Apparent relative impairment of 17,20-lyase activity
6. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome
7. Inhibitory effect of sandostatin on luteinizing hormone and ovarian steroids in polycystic ovary syndrome
8. Metformin
9. Thiazolidinediones in the treatment of insulin resistance and type II diabetes
10. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy
11. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in polycystic ovary syndrome
12. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens
13. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome
14. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome
15. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
16. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome
17. Can metformin reduce insulin resistance in polycystic ovary syndrome?
18. Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome
19. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion
20. Hirsutism: Implications, etiology, and management
21. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: Evidence that androgens impair insulin action in women
22. Insulin-sensitising agents in polycystic ovary syndrome
23. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss
24. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome
25. 17α-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss
26. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women
27. Assessment of insulin sensitivity in vivo
28. Effects of sex steroids on serum lipids and lipoproteins
29. Insulin resistance and lipid metabolism
30. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
31. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome
32. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells
33. Cyproterone acetate vs. hydrocortisone treatment in late onset adrenal hyperplasia